02256 ABBISKO-B
- 3.500
- +0.080+2.34%
ABBISKO-B News
Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination With Shanghai Allist's Furmonertinib
Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said its investigational non-small cell lung cancer drug ABSK043 would be clinically tested in combination with Furmonertinib Mesilate Tablets, acco
Heyu-B (02256.HK): Heyu Pharmaceutical announced the launch of a clinical study on ABSK043 combined with vometinib mesylate tablets to treat advanced non-small cell lung cancer
Heyu-B (02256.HK) announced that on May 9, 2024, Shanghai Heyu Biomedical Technology Co., Ltd. (Hoyu Pharmaceutical), a subsidiary of the company, announced that ABSK043, an oral small molecule PD-L1 inhibitor it is developing, will soon conduct clinical research on vometinib mesylate tablets independently developed by Shanghai Allis Pharmaceutical Technology Co., Ltd. (Shanghai Stock Exchange code: 688578) (trade name: Avexar, vometinib) for advanced non-small cell lung cancer. This collaborative study is a multi-center, open phase II clinical trial, including ABSK0
Heyu-B (02256.HK): Carrying out clinical research on ABSK043 combined with vometinib mesylate tablets to treat advanced non-small cell lung cancer
On May 9, Ge Longhui (02256.HK) announced that ABSK043, an oral small molecule PD-L1 inhibitor developed by it, will soon conduct clinical research on combination treatment for advanced non-small cell lung cancer with vometinib mesylate tablets (trade name: Avsha, “vometinib”) independently developed by Allis (688578.SH).
Heyu-B (02256): Heyu Pharmaceutical announced the launch of a clinical study on ABSK043 combined with vometinib mesylate tablets to treat advanced non-small cell lung cancer
Heyu-B (02256) issued an announcement. On May 9, 2024, the company's subsidiary Shanghai Heyu Biopharmaceuticals...
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
May 2 Repurchase Collection | Hang Seng Bank, Swire Group A and others bought back one after another. Of these, Hang Seng Bank spent HK$47.1617 million
According to documents disclosed by the Hong Kong Stock Exchange on May 3, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 450,000 common shares on May 2, involving an amount of HK$47.161,700. The repurchase price per share ranged from HK$105.4 to HK$102.9. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 7.984 million shares, accounting for 0.418% of the number of shares issued when the ordinary resolution was passed. ② $Taikoo
Goodwill B (02256.HK) spent HK$214,500 to buy back 64,000 shares on May 2
On May 2, Gelonghui (02256.HK) announced that it spent HK$214,500 to repurchase 64,000 shares on May 2.
Repurchase Collection on April 30 | Hang Seng Bank, Swire Group A, etc. bought back one after another. Of these, Hang Seng Bank spent HK$56.2511 million
According to documents disclosed by the Hong Kong Stock Exchange on May 2, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 540,000 common shares on April 30, involving an amount of HK$56.2511 million. The repurchase price per share ranged from HK$105 to HK$103.6. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 7.534 million shares, accounting for 0.394% of the number of shares issued when the ordinary resolution was passed. ② $Taikoo Shares
Goodwill B (02256.HK) spent HK$1.66 million to buy back 500,000 shares on April 30
On April 30, Gelonghui (02256.HK) announced that it spent HK$1.66 million to buy back 500,000 shares on April 30.
Goodwill B (02256): Yu Hongping was appointed as Joint Company Secretary
Heyu-B (02256) announced that Dr. Yu Hongping, the company's executive director, has been appointed as the company's joint company secretary...
April 26 Repurchase Collection | Hang Seng Bank, Swire Group A and others bought back one after another. Of these, Hang Seng Bank spent HK$61.74,141 million
According to HKEx's April 29 disclosure documents, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 26, involving an amount of HK$6,1714,400. The repurchase price per share ranged from HK$103.3 to HK$102.2. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) was 6.314 million shares, accounting for 0.33% of the number of shares issued when the ordinary resolution was passed. ② $too
On April 26, Heyu-B (02256) spent about HK$472,400 to buy back 149,000 shares
Goodwill B (02256) announced that on April 26, 2024, it cost approximately HK$472,400 to buy back 14.9...
Hong Kong Stock Announces Nuggets | CNOOC achieved net profit of 39.719 billion yuan in the first quarter, up 23.7% year-on-year
[Important matters] Xintong Medical-B (02160): Vitaflow Liberty received CE mark approval and honor-b (02256): FGFR4 inhibitor ipagotinib was certified as an orphan drug by the US FDA China Biopharmaceutical (01177): Class 1 innovative drug “TQA3038 (siRNA)” completed phase I clinical research Huatai Securities (06886) plans to cash out about US$1,793 million in China's Xincheng (01278) subsidiary investment of 5000 10,000 yuan acquisition of Meidi Pension Service
Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation
The US Food and Drug Administration granted orphan drug designation to Abbisko Cayman's (HKG:2256) irpagratinib medication for hepatocellular carcinoma or liver cancer, according to a Thursday filing
Repurchase Collection on April 24 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$82,6392 million
According to HKEx's April 25 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 1,285,200 common shares on April 23, involving an amount of HK$82,6392 million. The repurchase price per share ranged from HK$64.65 to HK$64.05. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 24, involving an amount of HK$597.95 million, with a repurchase price of HK$100.3 per share
Goodwill B (02256): The FGFR4 inhibitor ipagotinib was certified as an orphan drug by the US FDA
Heyu-B (02256) issued an announcement. The company's subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu...
Goodwill B (02256.HK) spent HK$156,000 to buy back 51,000 shares on April 24
On April 24, Gelonghui (02256.HK) announced that it spent HK$156,000 to buy back 51,000 shares on April 24.
Goodwill B (02256): Tian Huimin resigns as joint company secretary
Zhitong Finance App News, Heyu-B (02256) issued an announcement. Due to the need to invest more energy in other jobs, Tian Huimin has resigned as the company's co-company secretary, effective April 24, 2024.
Repurchase Collection on April 23 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$81.1047 million
According to HKEx's April 24 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 1,283,200 common shares on April 22, involving an amount of HK$81.1047 million. The repurchase price per share ranged from HK$63.55 to HK$62.95. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 23, involving an amount of HK$59.026,900, with a repurchase price of 98.95 per share
Analysis
Price Target
No Data
